

FIGURE 1: DISTRIBUTION OF COVID-19 H2020 PROJECTS ACCORDING TO MAJOR NEEDS BY ESTIMATED EU FINANCIAL CONTRIBUTION (M EURO)



€1 billion pledged from Horizon 2020

€780.8 million mobilised





FIGURE 2: DISTRIBUTION OF THE €1 BILLION INVESTED IN 2020 BY THE EU IN RESEARCH AND INNOVATION TO COMBAT COVID-19 (M EUROS)





EU-wide COVID-19 clinical trial networks

Large-scale studies for robust results

Contact: 22 July 2021


*Evelyn Depoortere, EU
evelyn.DEPOORTERE@ec.europa.eu*

Background & rationale


- Observed fragmentation of study initiatives
 - Call by EMA/CHMP to pool resources for large-scale multi-centre, multi-arm clinical trials
- Use of potential therapeutics outside of study/trial context
 - No contribution to evidence generation
- [ERAvsCORONA action plan](#)
 - 2nd priority action on extending and supporting large EU wide clinical trials for clinical management of COVID19 patients
- EU Strategy on COVID-19 therapeutics
 - Commits to ensuring access to and swift approval of large-scale clinical trials in the EU

EU-wide networks for COVID-19 clinical trials

Network for therapeutics



Network for vaccines



Trial Coordination Board

Core

- Projects
- Trials
- Observers

Extended

- Policy
- Regulators
- Scientists
- Industry


* Trial Coordination Board (TCB) & Joint Access Advisory Mechanism (JAAM)

Therapeutic trials

REMAP-CAP: Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia

- Set up under the [PREPARE](#) project (FP7, 2014-21), integrated in [RECOVER](#) project (H2020, 2020-22, 14 partners from 8 countries, €21M)
- Important preparedness investment, now international trial
- Innovative response-adaptive trial design, suited for pandemic response
- Results related to use of
 - Hydrocortisone, systemic Corticosteroids, Interleukin-6 Receptor Antagonists, therapeutic anticoagulation, Hydroxychloroquine and Chloroquine, Convalescent plasma

• <https://www.remapcap.org/> and <https://www.remapcap.eu>



Therapeutic trials (Ctd.)



DisCoVeRy & SolidAct trials

- Set up under EU-RESPONSE project (H2020, 2020-25, 21 partners, 16 countries, €16M)
- **SolidAct trial**
 - Pan-European adaptive platform trial involving around 15 European countries
 - Allowing for seamless transition from phase I/II trial
 - Currently testing Baricitinib
- **DisCoVeRy trial**
 - Phase III randomised control trial, FR add-on to WHO Solidarity
 - H2020 support to expand in Europe
 - Currently testing long-acting antibody combination (AZD7442)
 - Results on use of Hydroxychloroquine, Lopinavir, Interferon, and Remdesivir
- <https://eu-response.eu/>



Vaccine trials network: VACCELERATE


- **www.vaccelebrate.eu** □ Single entry-point to central vaccine trial platform
- Network of clinical trial sites and laboratories for high-quality vaccine trials
 - Capacity building, volunteer registries
- Close gaps in public health knowledge on COVID-19 vaccines
- Enable coordination & implementation of COVID-19 vaccine phase II & III trials
- Harmonised data, protocols and assays to improve knowledge transfer



VACCELERATE

VACCELERATE (Ctd.): Network building

- Clinical trial sites in 37 countries
 - For 444 sites detailed information is available;
 - includes 213 sites with pediatric trial capacity
- Access to 800 laboratories in 41 countries
- Tapping into COMBACTE's [CLIN-Net](#) & [LAB-Net](#)



VACCELERATE (Ctd.): Coordination

- Stakeholder working group
 - Strategic forum gathering industry, SME, public health authorities, ...
 - Participation of EMA and ECDC
- External Ethics and Scientific Advisory Board
 - Draw in external expertise
- <https://www.vaccelebrate.eu/>


VACCELERATE (Ctd.): Vaccine trials in preparation

- 2 adaptive platform trials
 - Platform trial 1: Adult population
 - Platform trial 2: Pediatric population
- Multiple sites in multiple countries, mainly EU
- VHP planned
- Planned to start in the Fall

Data sharing

European COVID-19 data portal

- Raw sequence data, open access
 - Analytical tools and visualisation
 - Linking of different types of data
 - Importance of standardisation
-
- <https://www.covid19dataportal.org/>



VEO report on mutations and variation in publicly shared SARS-CoV-2 raw sequencing data, Report No. 2, 11 Mar. 2021

<https://www.veo-europe.eu/>

The ReCoDID logo is a dark blue rectangular box with the text "Re CoDID" in white, uppercase, sans-serif font. The "o" in "Co" is stylized with a white outline.

Facilitating data & sample sharing between infectious disease cohort studies

<https://recodid.eu/>